| Business Summary | | ISIS
Pharmaceuticals,
Inc.
is
engaged
in
genomics-based
drug
discovery
and
development
focused
on
RNA
(ribonucleic
acid).
RNA
contains
all
of
the
information
the
cell
needs
to
produce
proteins.
Interaction
with
RNA
can
keep
disease-causing
proteins
from
being
produced.
The
Company
has
integrated
its
expertise
in
molecular
and
cellular
biology,
medicinal
chemistry,
RNA
biochemistry,
bioinformatics,
pharmacology
and
clinical
development
to
create
two
technologies.
Antisense,
the
Company's
leading
technology,
directly
uses
gene-sequencing
information
to
rationally
design
drugs.
From
this
technology,
the
Company
has
put
one
product
on
the
market
and
built
a
robust
pipeline
of
11
products
in
development,
of
which
six
products
are
in
late
stage
clinical
trials
(either
Phase
II
or
Phase
III). | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | ISIS
Pharmaceuticals
is
engaged
in
the
discovery
and
development
of
a
new
class
of
drugs,
antisense
oligonucleotides,
which
may
form
a
new
basis
for
therapeutic
drugs
that
are
safer
and
more
effective.
For
the
six
months
ended
6/30/01,
revenues
rose
11%
to
$12.2
million.
Net
loss
applicable
to
Common
rose
40%
to
$46.5
million.
Revenues
reflect
the
licensing
of
preclinical
Type
two
diabetes
antisense
drug
candidate.
Net
loss
reflects
increased
R&D
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Stanley Crooke, M.D., Ph.D., 56 Chairman,
CEO, and Pres | $658K | -- | B. Lynne Parshall, 46 CFO,
Exec. VP, Sec., Director | 503K | $1.6M | Patricia Lowenstam, 54 VP,
HR | -- | -- | Karen Lundstedt, 36 VP,
Investor Relations & Corp. Communications | -- | -- | C. Frank Bennett, Ph.D., 44 VP,
Biology | 311K | 72K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|